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Background: Inhaled therapy is the cornerstone of pharmacotherapy in patients with asthma
and chronic obstructive pulmonary disease (COPD). Appropriate inhalation device selection
is as important as drug choice but device-specific guidance appears to be lacking.
Methods: To quantify the level of inhalation-device recommendations in clinical guidelines, a
review was conducted by hand-searching national and international asthma and COPD guide-
lines (Global Initiative for Asthma [GINA] and Global initiative for chronic Obstructive Lung
Disease [GOLD] guidelines) and an international guideline on device selection (the American
College of Chest Physicians/American College of Asthma, Allergy, and Immunology [ACCP/
ACAAI]). For each guideline, the number of pages, tables/figures and references relating to
inhalation devices was identified.
Results: GINA and GOLD guidelines contain very little inhalation device-specific guidance
beyond recommendations for demonstrating and testing correct inhalation technique: <2%
of pages or references and <3% of tables/figures are dedicated to devices. Device-related con-
tent in the ACCP/ACAAI device selection guideline was considerably higher with 54% of pages,
88% of tables/figures and 82% of references, respectively. Results in national guidelines reflect
those on international guidelines.
Conclusions: These results indicate that there is a considerable lack of clear and specific
guidance regarding inhalation devices in current asthma/COPD guidelines. More robust studies) 243610325; fax: þ31 (0) 243610324.
G.umcn.nl (P.N.R. Dekhuijzen).
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hts reserved.
Inhaler guidance in current guidelines 695Figon the impact of inhalation devices are needed to increase the number of evidence statements
and recommendations regarding inhalation devices.
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Healthcare professionals are faced with a range of chal-
lenges when selecting the most appropriate inhalation
therapy for a patient with asthma or chronic obstructive
pulmonary disease (COPD). A number of different factors
can adversely affect outcomes, including incorrect diag-
nosis, poor compliance, and inadequate or inappropriate
therapy (Fig. 1) and the inhalation device to be used should
also be considered. Correct use of an appropriate inhala-
tion device enables medication to be effectively delivered
directly to the lungs, thus maximising clinical efficacy while
minimising potential systemic side effects [1]. Successful
delivery to the lungs is influenced by factors including
particle size, inhalation flow rate and inhaler resistance
[2,3]. These and other factors differ between inhalation
devices and can affect inhaler technique, patient satis-
faction and compliance with treatment.
Selection of themost appropriate inhalation therapy in an
effective inhaler that the patient can easily use correctly is
further complicated by the range of molecules available and
the fact that not all of themare available in all devices, along
with the ever-increasing variety of inhaler designs and
characteristics [4]. Incorrect inhaler technique can have
serious consequences for patients in terms of disease control
and quality of life [5e8]. These preventable consequences
further increase the burden of asthma and COPD both on the
individual and on society [9]. It is, therefore, important thature 1 Reasons for poor asthmclear and concise guidance is available to enable physicians
to select the most appropriate inhaler device to deliver the
medication they decide an individual patient needs.
Unfortunately, the Global Initiative for Asthma (GINA)
[10] and Global initiative for chronic Obstructive Lung
Disease (GOLD) [11] guidelines are both complex and
lengthy documents to absorb and implement. In addition,
they are pharmacologically oriented and provide limited
guidance regarding choice of devices. This study was con-
ducted to quantitatively assess the proportion of guideline
content specifically dedicated to handheld inhalation
devices (pressurised metered-dose inhalers [pMDIs] with or
without spacer devices and dry powder inhalers [DPIs]). The
level of guidance provided by evidence-based respiratory
guidelines on inhaler choice was also investigated and
recommendations on how this guidance could be improved
were provided.Methods
A review of inhalation-device recommendations in clinical
guidelines was performed by hand-searching major asthma
and COPD guidelines. These guidelines were identified by
searching the National Center for Biotechnology Informa-
tion, U.S. National Library of Medicine (PubMed) database
for publications with titles that contain the terms ‘COPD’ or
‘asthma’ and ‘guideline’ or ‘guidelines’. Using these resultsa control in clinical practice.
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local guidelines, reports from the following bodies/soci-
eties were selected for review:
 British Thoracic Society/Scottish Intercollegiate Guide-
line Network (BTS/SIGN) [12]
 Dutch Standard of COPD Care [13]
 GINA [10]
 GOLD [11]
 Italian Guidelines for Asthma, COPD and Rhinitis (LIBRA)
[14]
 International Primary Care Respiratory Group (IPCRG)
[15,16]
 National Institute for Health and Clinical Excellence
(NICE) [17]
 Haute Autorite´ de Sante´ (ANAES/HAS) [18]
 Swedish Medical Products Agency (La¨kemedelsverket)
[19,20]
 The French-speaking Society of Pneumology (SPLF) [21]
In addition, the American College of Chest Physicians/
AmericanCollegeofAsthma,Allergy, and Immunology (ACCP/
ACAAI) guideline on device selection was reviewed [22].
Although not disease specific, the ACCP/ACAAI guidelines
provide evidence-based recommendations on inhalation
devices for respiratory disease and were considered to be
relevant for inclusion. As this study is focused on evidence-
based guidelines for the management of respiratory dis-
ease, rather than guidance, the 2011 European Respiratory
Society/International Society for Aerosols in Medicine (ERS/
ISAM) task force report on the delivery of pharmaceutical
aerosols [23] was not included in the review.
For each guideline, the number of pages, tables/figures,
specific recommendations and references relating to inha-
lation devices was identified.Results
International guidelines
The proportion of device-related content in GINA and GOLD
guidelines is very low, with <2% of pages or references
dedicated to inhalation devices (Table 1), and 14 of 16 suchTable 1 The proportion of content specifically related to
inhalation devices in current international treatment
guidelines for asthma and COPD.
Guideline Number (%)
of pages
Number (%)
of tables/
figures
Number (%)
of references
GINA [10] 1.8/110 (1.6%) 1/37 (2.7%) 17/902 (1.8%)
GOLD [11] 0.66/78 (0.8%) 1/37 (2.7%) 5/488 (1.0%)
ACCP/ACAAI
[22]
20/37
(54.0%)
21/24
(87.5%)
116/142
(81.7%)
ACCP/ACAAI, American College of Chest Physicians/American
College of Asthma, Allergy, and Immunology; COPD, chronic
obstructive pulmonary disease; GINA, Global Initiative for
Asthma; GOLD, Global initiative for chronic Obstructive Lung
Disease.references for GINA and 4 of 5 references for GOLD were
published more than 5 years prior to the guideline publi-
cation. The level of device-specific content in tables and
figures is also low: GINA contains one table with a strategy
for choosing an inhalation device in children according to
age range, while the GOLD guideline contains one table
that outlines formulations and typical doses of COPD
medications including inhalers.
As expected, overone-half of thepagesof theACCP/ACAAI
device-selection guideline contain device-specific content
and more than three-quarters of the tables/figures and
references in this publication clearly relate to inhalation
devices (Table 1). Notably, one table describes the advan-
tages and disadvantages of different types of aerosol-
generating inhaler devices, including pMDIs and DPIs. How-
ever, 100of the116device-related referenceswerepublished
more than 5 years prior to the publication of this guideline.
The number of recommendations regarding inhalation
devices and specific recommendations according to patient
subgroup incurrent clinical guidelinesare reported inTable 2.
Both GINA and GOLD guidelines advocate that factors such as
cost, the ability and skill of the patient, preference and de-
vice availability should be taken into account when selecting
an inhalation device but provide little further guidance on the
specifics of these or other factors, such as patient age and the
types of drugs being administered (Table 2).
Inhalation-device recommendations in the ACCP/ACAAI
guideline are more all-encompassing and include both low-
and high-quality evidence. These recommendations are not
specific to patient subgroups (e.g. paediatrics or the elderly)
with the exception of a table on general age requirements for
the correct use of aerosol delivery device types based on the
National Asthma Education and Prevention program. How-
ever, guidance on selecting an appropriate inhalation device
and recommendations on appropriate devices for use in
various clinical settings is provided (Table 2).
Both GINA and GOLD guidelines recommend that a pa-
tient’s inhalation technique is assessed at every visit to
their clinician. However, no guidance on correct inhalation
technique is provided in the ACCP/ACAAI guideline and
none of the guidelines provide any specific information on
how clinicians should assess technique.
Generally, guidelines refer to pMDI or DPI universally
rather than to specific inhalation devices when making
recommendations. The GINA guideline does not mention any
branded inhalation devices while the GOLD guideline men-
tions the HandiHaler and Respimat devices in one para-
graph. The ACCP/ACAAI guideline mentions Combivent,
Diskhaler, Rotahaler, Spinhaler, Spiros, Turbuhaler
and Ventolin inhalers in the context of describing clinical
studies but does not provide any specific guidance.
Across all three guidelines, a notable proportion of
inhalation device-related content concerned the use of
spacer devices (Table 2).National guidelines
The proportion of inhalation device-related content in
current national treatment guidelines for asthma and COPD
reflects that of the international guidelines (see Online
supplementary materials for further details).
Table 2 Guidance relating to inhalation devices in current
international treatment guidelines for asthma, COPD and
pulmonary diseases.
Statement Guideline
GINA
[10]
GOLD
[11]
ACCP/
ACAAIa
[22]
Considerations for appropriate inhalation device selection
Patient’s ability to use
the device correctly
U U U
Patient preference U U
Availability of the drug/
device combination
U U
Compatibility between
the drug and delivery
device
U
Time/skills to properly
instruct the patient in
the use of the device
or to monitor
appropriate use
U
Cost of therapy U U
Potential for
reimbursement
U
Both pMDIs and DPIs are
appropriate for the
delivery of SABA and ICS
U U
Preferred device in children
<4 years, pMDI inhaler
plus dedicated spacer
with face mask
U n/a
4e6 years, pMDI inhaler
plus dedicated spacer
with mouthpiece
U n/a
>6 years, DPI, or breath-
actuated pMDI or pMDI
with spacer and
mouthpiece
U n/a
pMDI should be used with a
spacer device
Ub U Uc
Training in inhaler technique
is important/essential
U U U
ACCP/ACAAI, American College of Chest Physicians/American
College of Asthma, Allergy, and Immunology; COPD, chronic
obstructive pulmonary disease; DPI, dry powder inhaler; GINA,
Global Initiative for Asthma; GOLD, Global initiative for chronic
Obstructive Lung Disease; ICS, inhaled corticosteroids; n/a, not
applicable; MDI, metered-dose inhaler; pMDI; pressurised
metered-dose inhaler; SABA, short-acting b2-agonist.
a Only recommendations provided for the outpatient setting
are included.
b In children.
c Except for the delivery of SABAs where a MDI may be
used  a spacer or holding chamber.
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The results of this study indicate that current asthma and
COPD treatment guidelines lack clear and specific guidance
regarding inhalation devices. This is particularly notable inthe international GINA [10] and GOLD [15] guidelines, which
are used worldwide by respiratory clinicians and local so-
cieties/governing bodies as the basis for their diagnosis and
treatment strategies. These guidelines, of course, only
reflect published evidence and do not seek to offer
guidance where published evidence of acceptable quality
does not exist [24].
Unlike GINA and GOLD, the ACCP/ACAAI guideline is not
disease specific and contains recommendations for device
selection according to various settings (e.g. the emergency
department/hospital inpatient setting) rather than by
particular disease/patient groups [22]. These recommen-
dations were made by the authors of a systematic review
and meta-analysis that investigated whether device selec-
tion has an effect on the efficacy and tolerability of inhaled
corticosteroids, b2-agonists and anticholinergics, and
assessed the strength of recommendations on the basis of
the quality of the evidence presented and net benefit to
the patient. The authors concluded that there were no
differences between inhalation devices in terms of clinical
efficacy. However, this analysis only included randomised
controlled trials (RCTs), which frequently require good
inhaler technique as an inclusion criterion. Findings from
other studies that may have highlighted differences
between devices that impact on their effectiveness in the
real-world setting were excluded. Studies that were
included in the analysis were found to be heterogeneous in
terms of purpose, study design and patient selection. Few
studies were designed to compare inhalation devices and
inhalation technique was often not described. The doses
used in the bronchodilator studies that were included were
generally at the top of the doseeresponse curve. These
factors may, at least in part, explain the finding of similar
efficacy between different inhalers.
The 2011 ERS/ISAM task force report on the delivery of
pharmaceutical aerosols [23] recognises that patients
participating in RCTs receive more training in inhalation
technique and counselling on the importance of adherence
than patients who are receiving routine clinical care. Thus,
the recommendations provided in this report focused on
the patient-use aspect of inhalation devices with the aim of
educating prescribers. Unfortunately, as this statement is
not an evidence-based guideline, it was not eligible for
inclusion in this review.
Guidelines rely upon and reflect the quantity and quality
of published evidence currently available, so when there is
little high-quality evidence available, they are limited in
their ability to provide clear recommendations concerning
the importance of device choice in asthma and COPD.
More studies are needed to enable clear, concise and
specific guidance in evidence statements and guideline
recommendations. This ‘call to action’ [25] may finally be
receiving the attention it deserves with the January 2012
update of the BTS/SIGN guidelines [12]. This contains
recommendations for research including three key ques-
tions relating to inhalation devices: ‘What role does patient
preference play in deciding which inhaler to prescribe?
Does this improve compliance? Does this improve effec-
tiveness of treatment?’
Studies that randomise patients on the same therapy to
different devices could provide answers as to which devices
are more effective and most suitable for particular
698 P.N.R. Dekhuijzen et al.subgroups. Unfortunately, such studies are not necessarily
easy to design and conduct. Clinical guidelines prefer to
base their recommendations on double-blind, double-
dummy RCTs. Currently, published studies comparing
inhalation devices are predominantly single-sponsored
asthma studies that only provide patient-reported out-
comes data. The factors that may preclude classical evi-
dence studies on devices include:
e The Hawthorne effect [26] (improved compliance and
inhaler technique in RCTs may obscure real-world
differences between devices)
e Controlling bias in real-world studies (methodological
issues make it difficult to ensure that observed
differences in disease control are actually due to the
inhalation device)
e Ethics of randomisation (it would be unethical to ran-
domise patients to a device they are unable to use)
e Complexities of placebo-controlled and double-blind,
double-dummy studies (patients may receive several
different inhalers to maintain blinding to study treat-
ments; hence the effect of one inhalation device cannot
be evaluated)
e Single-sponsor studies (these studies could be biased
towards the product of the study sponsor).
Even if evidential studies could be conducted, they are
unlikely to provide a true reflection of the considerations
that need to be made when selecting an appropriate
inhalation device for the individual patient, as this depends
on a range of factors. These include objective factors, such
as the resistance and fine particle output characteristics of
the device, and often its cost, along with more subjective
elements, such as the patient’s dexterity, co-ordination
and inspiratory flow, previous experience with device,
acceptability, convenience and visual preference [2,3]. The
kind of research required to identify which devices are
most suitable in the clinical setting does not fit easily with
traditional evidence grading systems. Asthma and COPD are
complex chronic diseases and each patient has individual
requirements. Studies based on targeted, personalised
medicine may be more appropriate than classical studies
that generalise the population with grouped mean data.Recommendations to address this issue
More (and better) evidence
Clearly, more precise information about, and guidance on,
the use of inhalation devices is warranted as device choice
can have a significant impact on inhaler technique and
adherence to treatment [27], and more data are needed to
enable treatment guidelines to provide recommendations.
To this end, studies regarding the most appropriate devices
for patient subgroups, such as those with low inspiratory
flow rates, paediatric and elderly populations, or patients
with cognitive, visual and hearing impairment that make it
difficult for them to synchronise inhalation with inhaler
activation, would be of particular importance. Moreover,
these patient populations clearly indicate that an ‘ideal’
inhaler device, suitable for all patients of all types, is not
available at the present: in fact, some of these patientsmay benefit more from the use of a nebuliser rather than a
handheld inhaler, despite the relative lack of portability.
Trials to address the gaps in evidence in comparisons of
devices could use standard outcome measures (exacerba-
tion rate, symptom control and healthcare utilisation) and,
in addition, new specific endpoints such as ‘inability to
maintain correct use of a device’. This would involve
regular objective assessments of each patient’s inhaler
technique, either at home by a visiting specialist nurse or
technician, at additional study visits or by utilising tech-
nologies such as video links, telemetry and other moni-
toring techniques. Patient education on correct use of the
device would be an important aspect of such an assessment
study. The main study would remain a robustly designed
RCT, but if patients were unable to maintain correct use of
a device to which they were randomised, they would be
classed as a treatment failure and switched to an alterna-
tive treatment arm using a different device. Tools to help
identify suitable inhalers for individual patients should be
developed and validated. Cohort studies that utilise data-
bases similar to the Clinical Practice Research Datalink [28]
could also be viable. Step-by-step descriptions of how to
use or teach the use of different types of inhaler correctly
are currently lacking in the GINA and GOLD guidelines. Such
instructions are of vital importance if patients are to
benefit fully from an inhalation treatment and do, there-
fore, need to be addressed by guidelines. In particular,
differences between pMDIs and DPIs in preparation and
actuation should be clearly described. The importance of
checking and re-checking the patient’s inhaler use at each
visit should also be more firmly stated. Finally, criteria to
be considered for choosing the most appropriate inhaler for
an asthma or COPD patient, such as those recently pro-
posed by Newman [29], should be reported and discussed in
guidelines. The precision of dosing by the pulmonary route
can be improved by appropriate choice of inhaler device
and by patient education.
Education of healthcare professionals
The development and validation of appropriate educational
tools is necessary to assist clinicians and other healthcare
professionals who are involved in selecting inhalation de-
vices (i.e. ‘teach the teacher’) [30]. The ACCP/ACAAI meta-
analysis [22] proposed some general principles for selecting
and using inhalation devices while a small number of al-
gorithms have been proposed in papers by the Aerosol Drug
Management Team (ADMIT) [31].
Patient education
It is at least as important to educate patients, as they may
have assumptions and expectations regarding their health
status, health provider, and the balance of benefits and
side effects that influence their adherence to treatment
[32]. Training is crucial for correct inhaler technique and
this is supported in all of the international guidelines
included in this study. Practical training tools are available
to help both the physician and the patient to understand
how to use an inhalation device properly. Some provide
real-time feedback on use of the device while others
objectively assess compliance with treatment [30]. Face-
to-face training and follow-up (with the physician or with
a trained nurse) is also necessary to ensure correct inhaler
Inhaler guidance in current guidelines 699technique and treatment adherence but this could be
combined with electronic follow-up (e.g. via the internet,
smartphone applications and modern media), which also
has the potential to collect real-life data regarding medi-
cation use.
Conclusions
Clear and specific content on inhalation devices is scarce in
current asthma and COPD guidelines. Treatment choice
should strike a balance between appropriate medication
and inhalation device selection. More data are needed to
enable guidelines to provide clear, current information to
clinicians on how to appropriately assess patients and
match them to a suitable device. Despite the difficulties in
obtaining robust clinical data that can be translated into
guideline recommendations, there are potential solutions
such as the inclusion of ‘inability to maintain correct use of
a device’ as a study endpoint. Additionally, the value of
both healthcare professional and patient education should
not be overlooked.
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